Global Gabapentin Market Share, Size, Trends, Industry Analysis Report, By Dosage (Tablet, Capsule, Oral Solutions), By Type (Generic Branded), By Application, By Distribution Channel; By Region; Segment Forecast, 2023 - 2032

Global Gabapentin Market Share, Size, Trends, Industry Analysis Report, By Dosage (Tablet, Capsule, Oral Solutions), By Type (Generic Branded), By Application, By Distribution Channel; By Region; Segment Forecast, 2023 - 2032



The global gabapentin market size is expected to reach USD 3,036.38 million by 2032, according to a new study by Polaris Market Research. The report “Global Gabapentin Market Share, Size, Trends, Industry Analysis Report, By Dosage (Tablet, Capsule, Oral Solutions), By Type (Generic Branded), By Application, By Distribution Channel; By Region; Segment Forecast, 2022 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Global Gabapentin is effective in treating several types of seizures, including partial seizures and generalized seizures. It is often used as an adjunct therapy for individuals who are not responding to other antiepileptic medications. Gabapentin has also been shown to be effective in treating neuropathic pain, which is caused by damage to the nerves. This type of pain is often chronic and can be difficult to manage with traditional pain medications.

The FDA has approved the medication gabapentin for the treatment of neuropathic pain and seizures. It works by altering certain brain neurotransmitters, reducing seizure frequency and relieving nerve damage-related pain. The gabapentin has been involved off-mark for different circumstances. It has been used, for instance, to treat restless leg syndrome, bipolar disorder, and anxiety. Gabapentin may even be effective in treating alcohol withdrawal and dependence, according to some studies.

Gabapentin has negative effects despite its effectiveness. Tiredness, drowsiness, and dizziness are all common side effects. Speaking difficulties, hazy vision, and coordination issues may also occur in some people. Gabapentin may occasionally cause more serious side effects, including suicidal ideation, tongue or face swelling, and breathing difficulties. When the electrical activity in the brain becomes disrupted, seizures are a medical condition. Involuntary movements, unconsciousness, and other symptoms may result from this.

A type of pain known as neuropathic pain is brought on by nerve damage. This kind of aggravation can be ongoing and challenging to deal with customary agony meds. It has been demonstrated that gabapentin reduces neuropathic pain, which includes pain brought on by diabetic neuropathy and postherpetic neuralgia. Gabapentin has been used for a variety of other conditions in addition to its approved uses. A few examinations have recommended that gabapentin might be successful in treating tension, bipolar turmoil, and a tendency to fidget. It has additionally been utilized to assist with overseeing side effects of liquor reliance and withdrawal. Gabapentin, like any other medication, can cause side effects. Normal secondary effects incorporate unsteadiness, sluggishness, and exhaustion. Speaking difficulties, hazy vision, and coordination issues may also occur in some people.

Global Gabapentin Market Report Highlights

The capsule market is expected to expand quickly. The rising demand for dosage forms that are simple to swallow is one of the primary factors driving growth. Most of the time, capsules are easier to swallow than tablets, especially for people who have trouble swallowing, children, and the elderly.

The hospital pharmacy segment of the healthcare industry is anticipated to gain the most market share of all pharmacy segments. Hospital pharmacies are in charge of providing hospitalized patients with medications, medical supplies, and other healthcare products.

North America, Gabapentin is broadly endorsed and is among the main 30 most recommended prescriptions in the US. It is anticipated that the prevalence of neurological disorders and chronic pain will continue to drive up demand for gabapentin in North America.

The global players include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Lupin Limited, Mylan N.V., Cipla Limited, Hikma Pharmaceuticals PLC, Arbor Pharmaceuticals, Inc., Zydus Cadila Healthcare Limited, Glenmark Pharmaceuticals Ltd.

Polaris Market Research has segmented the Global Gabapentin market report based on Dosage, Type, Method, Application, Distribution Channel, and Region:

Global Gabapentin, Dosage Outlook (Revenue, USD Million, 2019-2032)

Capsule

Tablet

Global Gabapentin, Type Outlook (Revenue, USD Million, 2019-2032)

Branded

Generic

Global Gabapentin, Method Outlook (Revenue, USD Million, 2019-2032)

Column-based

Magnetic Beads

Reagent-based

Others

Global Gabapentin, Application Outlook (Revenue, USD Million, 2019-2032)

Neuropathic Pain

Epilepsy

Restless Legs Syndrome

Others

Global Gabapentin, Distribution Channel Outlook (Revenue, USD Million, 2019-2032)

Retail Pharmacy

Hospital Pharmacy

Online Pharmacy

Global Gabapentin, Regional Outlook (Revenue - USD Million, 2019-2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa


1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. Global Gabapentin Market Insights
4.1. Gabapentin – Industry Snapshot
4.2. Gabapentin Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Increasing entry of generics in the market
4.2.1.2. Rising awareness campaigns and prevention programs
4.2.2. Restraints and Challenges
4.2.2.1. Increased Misuse Of Gabapentin
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTLE Analysis
4.5. Gabapentin Industry Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis
5. Global Gabapentin Market, by Dosage
5.1. Key Findings
5.2. Introduction
5.2.1. Global Gabapentin Market, by Dosage, 2019-2032 (USD Million)
5.3. Capsule
5.3.1. Global Gabapentin Market, by Capsule, by Region, 2019-2032 (USD Million)
5.4. Tablet
5.4.1. Global Gabapentin Market, by Tablet, by Region, 2019-2032 (USD Million)
6. Global Gabapentin Market, by Application
6.1. Key Findings
6.2. Introduction
6.2.1. Global Gabapentin Market, by Application, 2019-2032 (USD Million)
6.3. Neuropathic Pain
6.3.1. Global Gabapentin Market, by Neuropathic Pain, by Region, 2019-2032 (USD Million)
6.4. Epilepsy
6.4.1. Global Gabapentin Market, by Epilepsy, by Region, 2019-2032 (USD Million)
6.5. Restless Legs Syndrome
6.5.1. Global Gabapentin Market, by Restless Legs Syndrome, by Region, 2019-2032 (USD Million)
6.6. Others
6.6.1. Global Gabapentin Market, by Others, by Region, 2019-2032 (USD Million)
7. Global Gabapentin Market, by Distribution Channel
7.1. Key Findings
7.2. Introduction
7.2.1. Global Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
7.3. Retail Pharmacy
7.3.1. Global Gabapentin Market, by Retail Pharmacy, by Region, 2019-2032 (USD Million)
7.4. Hospital Pharmacy
7.4.1. Global Gabapentin Market, by Hospital Pharmacy, by Region, 2019-2032 (USD Million)
7.5. Online Pharmacy
7.5.1. Global Gabapentin Market, by Online Pharmacy, by Region, 2019-2032 (USD Million)
8. Global Gabapentin Market, by Type
8.1. Key Findings
8.2. Introduction
8.2.1. Global Gabapentin Market, by Type, 2019-2032 (USD Million)
8.3. Branded
8.3.1. Global Gabapentin Market, by Branded, by Region, 2019-2032 (USD Million)
8.4. Generic
8.4.1. Global Gabapentin Market, by Generic, by Region, 2019-2032 (USD Million)
9. Global Gabapentin Market, by Geography
9.1. Key findings
9.2. Introduction
9.2.1. Gabapentin Market Assessment, By Geography, 2019-2032 (USD Million)
9.3. Gabapentin Market – North America
9.3.1. North America: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.3.2. North America: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.3.3. North America: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.3.4. North America: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.3.5. Gabapentin Market – U.S.
9.3.5.1. U.S.: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.3.5.2. U.S.: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.3.5.3. U.S.: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.3.5.4. U.S.: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.3.6. Gabapentin Market – Canada
9.3.6.1. Canada: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.3.6.2. Canada: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.3.6.3. Canada: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.3.6.4. Canada: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.4. Gabapentin Market – Europe
9.4.1. Europe: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.4.2. Europe: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.4.3. Europe: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.4.4. Europe: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.4.5. Gabapentin Market – UK
9.4.5.1. UK: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.4.5.2. UK: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.4.5.3. UK: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.4.5.4. UK: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.4.6. Gabapentin Market – France
9.4.6.1. France: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.4.6.2. France: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.4.6.3. France: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.4.6.4. France: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.4.7. Gabapentin Market – Germany
9.4.7.1. Germany: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.4.7.2. Germany: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.4.7.3. Germany: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.4.7.4. Germany: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.4.8. Gabapentin Market – Italy
9.4.8.1. Italy: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.4.8.2. Italy: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.4.8.3. Italy: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.4.8.4. Italy: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.4.9. Gabapentin Market – Spain
9.4.9.1. Spain: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.4.9.2. Spain: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.4.9.3. Spain: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.4.9.4. Spain: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.4.10. Gabapentin Market – Netherlands
9.4.10.1. Netherlands: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.4.10.2. Netherlands: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.4.10.3. Netherlands: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.4.10.4. Netherlands: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.4.11. Gabapentin Market – Russia
9.4.11.1. Russia: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.4.11.2. Russia.: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.4.11.3. Russia: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.4.11.4. Russia: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.5. Gabapentin Market – Asia Pacific
9.5.1. Asia Pacific: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.5.2. Asia Pacific: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.5.3. Asia Pacific: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.5.4. Asia Pacific: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.5.5. Gabapentin Market – China
9.5.5.1. China: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.5.5.2. China.: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.5.5.3. China: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.5.5.4. China: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.5.6. Gabapentin Market – India
9.5.6.1. India: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.5.6.2. India.: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.5.6.3. India: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.5.6.4. India: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.5.7. Gabapentin Market – Japan
9.5.7.1. Japan: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.5.7.2. Japan.: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.5.7.3. Japan: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.5.7.4. Japan: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.5.8. Gabapentin Market – Malaysia
9.5.8.1. Malaysia: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.5.8.2. Malaysia.: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.5.8.3. Malaysia: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.5.8.4. Malaysia: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.5.9. Gabapentin Market – Indonesia
9.5.9.1. Indonesia: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.5.9.2. Indonesia.: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.5.9.3. Indonesia: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.5.9.4. Indonesia: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.5.10. Gabapentin Market – South Korea
9.5.10.1. South Korea: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.5.10.2. South Korea.: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.5.10.3. South Korea: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.5.10.4. South Korea: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.6. Gabapentin Market – Middle East & Africa
9.6.1. Middle East & Africa: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.6.2. Middle East & Africa: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.6.3. Middle East & Africa: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.6.4. Middle East & Africa: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.6.5. Gabapentin Market – Saudi Arabia
9.6.5.1. Saudi Arabia: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.6.5.2. Saudi Arabia: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.6.5.3. Saudi Arabia: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.6.5.4. Saudi Arabia: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.6.6. Gabapentin Market – South Africa
9.6.6.1. South Africa: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.6.6.2. South Africa: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.6.6.3. South Africa: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.6.6.4. South Africa: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.6.7. Gabapentin Market – Israel
9.6.7.1. Israel: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.6.7.2. Israel: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.6.7.3. Israel: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.6.7.4. Israel: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.6.8. Gabapentin Market – UAE
9.6.8.1. UAE: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.6.8.2. UAE: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.6.8.3. UAE: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.6.8.4. UAE: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.7. Gabapentin Market – Latin America
9.7.1. Latin America: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.7.2. Latin America: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.7.3. Latin America: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.7.4. Latin America: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.7.5. Gabapentin Market – Mexico
9.7.5.1. Mexico: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.7.5.2. Mexico: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.7.5.3. Mexico: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.7.5.4. Mexico: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.7.6. Gabapentin Market – Brazil
9.7.6.1. Brazil: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.7.6.2. Brazil: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.7.6.3. Brazil: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.7.6.4. Brazil: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
9.7.7. Gabapentin Market – Argentina
9.7.7.1. Argentina: Gabapentin Market, by Dosage, 2019-2032 (USD Million)
9.7.7.2. Argentina: Gabapentin Market, by Type, 2019-2032 (USD Million)
9.7.7.3. Argentina: Gabapentin Market, by Application, 2019-2032 (USD Million)
9.7.7.4. Argentina: Gabapentin Market, by Distribution Channel, 2019-2032 (USD Million)
10. Competitive Landscape
10.1. Expansion and Acquisition Analysis
10.1.1. Expansion
10.1.2. Acquisitions
10.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
11.1. Pfizer Inc
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Benchmarking
11.1.4. Recent Development
11.2. Teva Pharmaceutical Industries Ltd
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Benchmarking
11.2.4. Recent Development
11.3. Sun Pharmaceutical Industries Ltd.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Benchmarking
11.3.4. Recent Development
11.4. Aurobindo Pharma Ltd
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Benchmarking
11.4.4. Recent Development
11.5. Lupin Limited
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Benchmarking
11.5.4. Recent Development
11.6. Mylan N.V
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Benchmarking
11.6.4. Recent Development
11.7. Cipla Limited
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Benchmarking
11.7.4. Recent Development
11.8. Hikma Pharmaceuticals PLC
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Benchmarking
11.8.4. Recent Development
11.9. Arbor Pharmaceuticals, Inc
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Benchmarking
11.9.4. Recent Development
11.10. Zydus Cadila Healthcare Limited
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Benchmarking
11.10.4. Recent Development
11.11. Glenmark Pharmaceuticals Ltd
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Benchmarking
11.11.4. Recent Development
11.12. Wockhardt Ltd
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Benchmarking
11.12.4. Recent Development

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings